Abemaciclib (Verzenio, Verzenios)

Medicine at a glance

Abemaciclib is a targeted cancer treatment taken as tablets. Verzenio and Verzenios are verified brand names in the sources listed below. Your pack may use a different name; check the active ingredient and strength with your pharmacist. A brand name in this article does not establish availability in India.

This article explains taking abemaciclib, managing its effects and recognising problems that need help. Read it alongside your prescription and the leaflet supplied with your medicine. Your oncology team chooses the dose, accompanying treatments and monitoring for you. Do not change these yourself.

What abemaciclib is and how it works

Cells use proteins called cyclin-dependent kinases 4 and 6, or CDK4 and CDK6, to help control division. Abemaciclib blocks these proteins. This can slow the multiplication of cancer cells that depend on this pathway. It is a CDK4/6 inhibitor, a type of targeted therapy, rather than conventional chemotherapy or an immune checkpoint inhibitor.

Targeting a particular pathway does not restrict every effect to cancer cells. Healthy tissues can also be affected, which explains why an oral targeted treatment still needs blood tests and careful safety advice. Taking it at home does not make those checks optional.

Abemaciclib is often prescribed with endocrine therapy, also called hormone therapy. The treatments act in different ways. Your team should explain the purpose of each medicine so that you know which tablets or injections continue if one treatment is paused.

How the team decides whether it is suitable

The decision considers your diagnosis, pathology results, previous treatment, overall health and applicable prescribing information. Important results include hormone receptor status and HER2 status. Hormone receptors indicate whether hormones can help drive cancer growth. HER2 is another protein involved in cell growth. These results help identify whether abemaciclib fits your treatment plan; they are not a guarantee of benefit.

Discuss what treatment is intended to achieve and how success will be assessed. The team also considers existing diarrhoea, infection, liver disease, kidney problems, lung symptoms and a history of blood clots. Bring up previous difficulty tolerating cancer treatment and any concerns about taking tablets regularly.

For some accompanying endocrine medicines, a blood test for an ESR1 gene change is also important. ESR1 helps control the oestrogen receptor; changes can affect how a cancer responds to hormone treatment. This is a selection test for a particular treatment plan, not a test that everyone taking abemaciclib necessarily needs.

Menopausal status and the chosen endocrine medicine affect whether hormone-suppressing injections are needed. Some premenopausal or perimenopausal patients, and some men, need a gonadotropin-releasing hormone agonist alongside treatment. Abemaciclib does not replace this medicine or act as contraception.

Before treatment starts

Your team checks a full blood count and liver function. Kidney function and blood salts may also be assessed. A pregnancy test is needed before starting if you could be pregnant. Depending on your history and local practice, additional tests, including viral screening, may be appropriate. Tell the team about previous hepatitis or other significant infections.

Provide an up-to-date list of prescriptions, medicines bought without a prescription, herbal products and supplements. Include occasional medicines and products you have recently stopped. Mention allergies and planned operations or dental work. The pharmacist needs to check the actual products, not just the reasons you take them.

Before the first dose, have the prescribed anti-diarrhoea medicine and clear instructions for using it. Know how to contact the treating hospital outside normal hours, when to have blood tests and how to obtain the next supply. Ask the team to explain any instructions you cannot follow easily at home.

How to take abemaciclib

Timing and treatment length

Abemaciclib is usually taken twice daily, at consistent morning and evening times, approximately 12 hours apart. There is normally no planned weekly break. Some treatment plans specify about two years; others continue while benefit and tolerability justify treatment. Your planned duration should be clear from your own treatment discussion.

A commonly prescribed starting dose with endocrine therapy is 150 mg twice daily. Different prescriptions are possible, including a different starting dose when used alone, lower doses for side effects or interactions, and once-daily dosing in severe liver impairment. These are examples, not instructions to adjust your dose. Check the strength every time a new supply is dispensed.

Food and swallowing

You can take abemaciclib with or without food. Swallow tablets intact with water; do not crush, split or chew them. Avoid grapefruit and grapefruit juice. Do not take damaged or broken tablets.

If swallowing is difficult or you use a feeding tube, contact the oncology pharmacist before the next dose. The reviewed labels do not provide a home dispersion or feeding-tube method. Do not improvise one. Verzenios tablets contain lactose; discuss known sugar intolerances with your pharmacist.

Missed doses and vomiting

If you miss a dose, leave it out and take the next prescribed dose at the usual time. If you vomit after a dose, do not replace it. Never double the next dose. Report repeated vomiting or missed doses so the team can help you maintain a workable schedule. If you take too much, seek medical advice immediately and have the pack available.

Storage and safe handling

Keep tablets safely away from children and pets, in their supplied packaging unless the pharmacist advises otherwise. Follow the storage instructions on your own pack. US Verzenio specifies 20–25°C (68–77°F), with permitted temporary excursions to 15–30°C (59–86°F); EU Verzenios states that no special storage conditions are required. Neither instruction makes a hot car a suitable storage place.

Do not share tablets. Ask the dispensing pharmacy how to return unwanted medicine; do not flush it down a drain. A caregiver should follow the pharmacist’s handling advice, particularly for damaged tablets.

Monitoring and checking whether treatment is working

Blood counts and liver tests are usually checked before treatment, every two weeks for the first two months, then monthly for the next two months, and thereafter as clinically needed. Your team may test more often if results or symptoms cause concern. Keep appointments even when you feel well: some changes show in blood tests before you notice symptoms.

Response assessment depends on the treatment purpose. It may involve symptom review, examination and scans when appropriate. Side effects do not tell you whether the treatment is working, and having few side effects does not show that it is ineffective.

Abemaciclib can increase a blood marker called creatinine by changing how the kidneys move it into urine, without necessarily reducing kidney filtration. The team should use measures that do not depend on creatinine alone, such as cystatin C, to assess kidney function during treatment. However, dehydration or genuine kidney injury can also occur. Reduced urine or severe dizziness must not be dismissed as an expected laboratory effect.

Treatment may be paused, reduced or stopped to manage toxicity. A prescribed break is part of medical management, not something to compensate for with extra tablets later. Ask for the restart date and dose in clear written instructions.

Common side effects and practical management

You will not necessarily develop every effect described here. The combination of medicines, dose and your health influence your experience. Report symptoms early rather than waiting until they interfere with eating, sleep or daily activities.

Diarrhoea and dehydration

Diarrhoea is particularly important with abemaciclib and often begins early, including during the first week. At the first loose stool, start the anti-diarrhoea medicine prescribed for you, increase oral fluids as advised, and notify your oncology team. Do not wait until diarrhoea is severe before making contact.

Keep track of bowel movements compared with your usual pattern, the medicines taken, fluid intake and urine output. Frequent small drinks may be easier to manage than a large glass at once. Ask whether an oral rehydration solution is appropriate, especially if you have kidney or heart problems or a fluid restriction.

If diarrhoea is not clearly improving within 24 hours despite treatment, contact the team again urgently and obtain instructions before further abemaciclib doses. The prescribing information requires a treatment pause for persistent moderate diarrhoea and for severe diarrhoea. Do not try to grade the problem yourself or keep taking tablets through uncontrolled symptoms.

Do not wait 24 hours if you have blood in the stool, fever, severe abdominal pain, marked dizziness, very little urine or cannot keep fluids down. These need prompt assessment. Severe weakness, confusion or collapse requires emergency help. Diarrhoea may have another cause, including infection, so avoid assuming every episode is simply the medicine.

Small meals and temporary changes to foods that worsen symptoms may help. Avoid alcohol and excessive caffeine while diarrhoea is active. Tell the team if eating becomes difficult; prolonged restrictive diets can create other problems.

Low blood counts and infection

Abemaciclib can reduce neutrophils, white blood cells that help fight infection. You may have no warning symptoms until an infection starts. Fever, chills, a new cough, painful urination or suddenly feeling very unwell should prompt immediate contact with your oncology service. A serious infection can occur without a high temperature.

Red blood cells carry oxygen. A low level, called anaemia, can contribute to tiredness or breathlessness. Platelets help stop bleeding; low platelets can cause unusual bruising or bleeding. Report these changes, and seek emergency care for heavy bleeding or severe breathlessness. Do not assume breathlessness is anaemia without assessment.

Nausea and reduced appetite

Use anti-sickness medicine as prescribed. Try smaller portions at regular intervals and tell the team if nausea prevents you taking medicines or drinking. Record any weight loss. Persistent vomiting needs assessment, rather than repeatedly missing food and fluids. A dietitian can help adapt meals to your preferences and symptoms.

Tiredness and dizziness

Plan demanding tasks for your better times of day and accept help with practical jobs. Gentle activity, balanced with rest, may help if your team considers it safe. Persistent or worsening fatigue deserves review because infection, anaemia, poor intake and sleep problems can contribute. Avoid driving or operating machinery when dizzy, unusually tired or unable to concentrate safely.

Mouth skin hair and nail changes

Mouth soreness, altered taste, rash, itching, dry skin, hair thinning or loss and nail changes can occur. Use gentle mouth care and a soft toothbrush. Report ulcers that limit drinking or eating. Ask about suitable moisturisers and treatments for an uncomfortable rash rather than trying strong medicated products yourself.

Hair changes vary and may also reflect accompanying treatment. Discuss practical support if this is distressing. Seek urgent assessment for a rapidly spreading rash, blistering, peeling skin or a rash involving the mouth or eyes.

Less common but important side effects

Lung inflammation

Abemaciclib can cause inflammation inside the lungs, sometimes called pneumonitis or interstitial lung disease. It can be serious. Contact the team urgently for a new or worsening cough or shortness of breath, with or without fever. Infection and blood clots can cause similar symptoms and need different treatment. Severe breathing difficulty requires emergency care.

Blood clots and arterial events

A clot in a vein may cause one-sided leg or arm swelling, warmth or pain. A clot travelling to the lungs can cause sudden breathlessness, chest pain or coughing up blood. Obtain urgent assessment for limb symptoms and emergency help for chest or breathing symptoms.

European product information also warns of a potential increased risk of serious arterial events, including heart attack and stroke, observed with endocrine combinations. Sudden facial droop, arm weakness, speech difficulty or persistent crushing chest pain is an emergency. Do not start aspirin or a blood thinner yourself to prevent clots.

Liver injury and eye problems

Liver inflammation may first appear in blood tests. Contact the team promptly for yellow skin or eyes, dark urine, pale stools or upper abdominal pain. Do not wait for the next scheduled test.

Watery eyes can occur. New flashes or floaters, eye pain, light sensitivity or changed vision need prompt medical assessment; do not assume these are harmless treatment effects. The European information includes corneal inflammation and visual disturbances.

Other medicines supplements and vaccinations

Abemaciclib is broken down partly by a liver enzyme called CYP3A. Medicines that affect this enzyme can change exposure to abemaciclib. Examples needing review include clarithromycin, azole antifungal medicines, ritonavir-containing treatments, rifampicin, carbamazepine, phenytoin and St John’s wort. Grapefruit is also relevant. This is not a complete interaction list.

Some interacting medicines increase side effects; others can reduce treatment effect. Do not stop an essential medicine yourself. Let the oncology pharmacist coordinate alternatives or dose changes, including when another clinician prescribes a short course. European information also flags possible interactions involving medicines such as digoxin and dabigatran.

Discuss vaccination timing with your oncology team. Live vaccines may be unsuitable during immunosuppressive treatment, while the response to other vaccines can be reduced. Do not assume every vaccine is prohibited. Include travel vaccines in advance planning.

Additional instructions for accompanying endocrine medicines

If imlunestrant accompanies abemaciclib, its food and missed-dose rules are different: it needs an empty stomach, while abemaciclib does not. Have the pharmacist write a timetable for both. Imlunestrant also requires monitoring of blood fats, including cholesterol and triglycerides.

If camizestrant is prescribed alongside abemaciclib, the team checks a heart tracing (ECG) before treatment, weekly for the first two weeks and periodically afterwards, and checks and corrects blood salts. Heart-rate monitoring may be more frequent during the first month. Camizestrant can slow the heartbeat and affect vision. Report palpitations or new visual symptoms promptly; fainting, chest pain or severe breathlessness needs emergency care. These are accompanying-medicine precautions, not requirements for every person taking abemaciclib.

Everyday life during treatment

Eating and drinking: Aim for adequate food and fluid intake rather than a special anticancer diet. Keep the diarrhoea plan accessible. Tell the team about supplements marketed for immunity or cancer before using them.

Work and activity: The effect on daily life varies. Plan access to a toilet, drinking water and rest where needed. A flexible work schedule may help during early treatment and dose changes. Gentle exercise should fit your energy and medical advice.

Travel: Discuss trips around monitoring and supply arrangements. Carry medicines in labelled packaging and plan how to obtain medical help away from home. Ask the pharmacist how to manage time-zone changes without bringing doses too close together.

Infection and dental care: Wash hands regularly, avoid close contact with people who are unwell and handle food safely. Tell your dentist and any surgical team that you take abemaciclib before procedures; blood counts and treatment timing may affect planning.

Sex and emotional wellbeing: Intimacy can change because of fatigue, symptoms or accompanying endocrine therapy. Raise discomfort, anxiety or low mood with the team. Contraception and any barrier precautions need a specific plan; neither absent periods nor reduced fertility proves pregnancy is impossible.

Fertility contraception pregnancy and breastfeeding

Abemaciclib can harm a developing baby. If you could become pregnant, use effective contraception during treatment and for at least three weeks after the last dose. European information advises highly effective methods and notes uncertainty about the reliability of systemic hormonal contraception with abemaciclib. Agree a suitable method with your oncology team; do not choose or change hormonal contraception yourself.

Patients taking abemaciclib who have a partner who could become pregnant should also obtain a contraception plan: accompanying medicines can impose specific precautions for male patients and their partners.

Notify the team promptly if pregnancy is suspected or confirmed. Men considering future parenthood should discuss possible effects on fertility; animal findings suggest male fertility may be impaired. Effects in humans are not fully established. Discuss fertility preservation before treatment where relevant.

Do not breastfeed during treatment or for at least three weeks after the last dose, following US prescribing information. Other medicines may require longer contraception or breastfeeding restrictions. Use the longest interval required by your complete treatment plan, confirmed by the team, rather than treating three weeks as universal permission to conceive or breastfeed.

After treatment finishes

Agree a follow-up plan covering blood tests, persistent symptoms and any accompanying endocrine treatment. Do not assume stopping abemaciclib means stopping every cancer medicine. Return leftover tablets through the pharmacy’s recommended route.

Continue the agreed reproductive precautions. Report ongoing diarrhoea, new breathing symptoms, fever or other concerning changes even after the final tablet. Recovery is individual; a symptom that persists deserves assessment rather than a promise that it will disappear by a fixed date.

Frequently asked questions